Summary of Interim Report January - June 2020, Dicot AB

Press release: Uppsala, August 27, 2020. A summary of the Interim report January - June 2020, for Dicot AB (publ) is now avalible on the company webbsite www.dicot.se .

Second Quarter 2020

  • Net sales amounts to KSEK 0 (0)
  • Earnings for the period amounts to KSEK -3 152 (-2 783).
  • Earnings per share -0.18 (-0.36) SEK

January - June 2020

  • Net sales amounts to KSEK 0 (0)
  • Earnings for the period amounts to KSEK -9 724 (-6 682).
  • Earnings per share -0.57 (-0.86) SEK

Statement from the CEO

The second quarter of the year has been marked by a shift in the way we work. Dicot is a company that is used to working remotely with our partners around the world. But under the current circumstances, we have had to switch to a more digital way of working from home, which has worked very well.

Our production partner in India, Anthem Bioscience, has been affected by the pandemic and was therefore closed during April and part of May. Consequently, the project was delayed by several months. However, Anthem has resumed operations since mid-May and the extract that was produced by Ardena in Södertälje at the beginning of the year was sent to Anthem during the summer and is now the starting material for the drug substance to be produced this autumn.

The first study at Pelvipharm, where the effect on erection in an animal model was studied, is completed. The final report will be published in early September and further studies are planned to provide information on the mechanism of action. The collaboration with our partner Pelvipharm has been outstanding and the level of professionalism continues to be very high.

In April, a retrospective study was initiated on the use of folk medicine as a traditional natural remedy for sexual dysfunction in Madagascar. Our drug candidate Libiguin® was discovered through studies of active components in the roots of a tree growing in Madagascar. During April and May, more than 200 men using a drink prepared by the root and bark were interviewed and an overwhelming majority of the men were very satisfied with the drink and its results. This strengthens our hopes that the effect of Libiguin® is more long-lasting than existing treatments. No severe side effects have been reported by the men who in many cases have used the drink regularly for many years.

In April Dicot's board of directors decided to carry out a rights issue earlier than planned to ensure successful implementation of the preclinical program. The decision was also affected by the ongoing pandemic. The rights issue was decided in the Annual General Meeting in May and carried out in June in a very successful manner. In total, the issue was oversubscribed to 326 percent and provides the company with capital for continued preclinical work.

During the spring, we have also focused on strengthening our communication. Our website now has a patient tab where we inform about sexual dysfunctions and there is the opportunity to ask questions anonymously to our clinical expert Dr Elin Gahm. As a step towards reaching the international market for sexual dysfunction, an English version of the website has also been launched.

I feel grateful for the positive implementation of the issue and the solid trust that our shareholders have shown - it strengthens us for the future. The work continues to progress for us to proceed to clinical studies. In conclusion I would also like to thank our partners and employees.

For further information, please contact:

Göran Beijer, CEO

Tel: +46 (0) 706 63 60 09

E-mail: goran.beijer@dicot.se

Jessica Roxhed, CFO

Tel: +46 70-394 94 98

Email: jessica.roxhed@dicot.se

About Dicot AB                                                                     

Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients' lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company's lead product, Libiguin®, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the Spotlight Stock Market and has approximately 1,600 shareholders. For more information see www.dicot.se.

Dicot rapporterar positiva resultat från studie med läkemedelskandidaten Libiguin ® för behandling av sexuell dysfunktion

Pressmeddelande: Uppsala, 14 september 2020. Dicot meddelar idag att de första resultaten från djurstudier utförda tillsammans med Pelvipharm har erhållits. Resultaten visar att Dicots läkemedelskandidat Libiguin® gav en signifikant och dosberoende effekt på erektion jämfört med placebo vid samtliga uppmätta parametrar i Pelvipharms etablerade djurmodeller. Nästa steg inkluderar ytterligare utvärdering tillsammans med Pelvipharm för att optimera kommande studie på bästa sätt. Pelvipharm SAS är ett världsledande prekliniskt kontraktslaboratorium (CRO) specialiserade på utvärdering av sexuell dysfunktion i djurmodeller och fler studier med Libiguin® är planerade i samarbetet.


Dicot AB delårsrapport januari - juni 2020

Pressmeddelande: Uppsala, 27 augusti 2020. Dicot ABs (publ) delårsrapport för januari - juni 2020 finns nu tillgänglig på bolagets hemsida www.dicot.se.


Summary of Interim Report January - June 2020, Dicot AB

Press release: Uppsala, August 27, 2020. A summary of the Interim report January - June 2020, for Dicot AB (publ) is now avalible on the company webbsite www.dicot.se .


Flaggningsmeddelande

Pressmeddelande: Uppsala 17 juli 2020. Dicot AB (publ) ("Dicot" eller "Bolaget") meddelar idag den 17 juli, följande flaggningsmeddelande till följd av Bolagets genomförda företrädesemission.


Disclosure Notice - Major shareholding notification

Press release: Uppsala, July 17, 2020. Dicot AB (publ) ("Dicot" or the "Company") announces today, July 17, the following disclosure notice as a result of the Company's completed rights issue.


Omräkning av teckningsoptioner av serie 2019/2020

Pressmeddelande: Uppsala 8 juli 2020. Dicot AB (publ) ("Dicot") kommer i enlighet med villkoren för utgivna teckningsoptioner av serie 2019/2020 genomföra en omräkning enligt optionsvillkoren till följd av den senaste genomförda emissionen av units som offentliggjordes den 23 april 2020. Omräkning kommer ske av dels teckningskursen vid teckning av aktier genom utnyttjande av teckningsoption och dels av antalet aktier som varje teckningsoption berättigar till teckning av. Information om omräkning av optionsvillkor framgår nedan.


Adjustments of warrants of series 2019/2020

Press release: Uppsala, July 8 2020. Dicot AB (publ) ("Dicot") will, in accordance with the terms for the warrants 2019/2020, carry out a recalculation in accordance with the warrant terms as a result of the latest completed rights issue of units published on April 23, 2020. There will be an adjustment of both subscription price and the number of shares that each warrant entitles to subscribe for. Information regarding the adjustments of option terms is shown below.


Dicot AB genomför riktad nyemission till garanter i samband med den företrädesemission som övertecknades

Pressmeddelande: Uppsala 7 juli 2020. Dicot AB (publ) ("Dicot" eller "Bolaget") har genomfört den företrädesemission om 21,8 MSEK som offentliggjordes den 23 april 2020 och som godkändes av årsstämman den 26 maj 2020 ("Företrädesemissionen"). I samband härmed genomförs, i enlighet med de garantiavtal som upprättats, en riktad nyemission av aktier till de garanter i Företrädesemissionen som valt att erhålla garantiersättning i form av nyemitterade aktier i Bolaget ("Ersättningsemissionen"). Teckningskursen i Ersättningsemissionen är fastställd till 1,80 SEK per aktie och betalning sker genom kvittning av garanternas fordringar.


Dicot resolves on a directed issue of shares (compensation issue) to guarantors in conjunction with the oversubscribed rights issue

Press release: Uppsala, July 7, 2020. Dicot AB ("Dicot" or the "Company") has completed the rights issue of units amounting to SEK 21.8 million, which was disclosed on April 23, 2020 and resolved by the annual general meeting on May 26, 2020 (the "Rights Issue") In connection herewith, in accordance with the underwriting commitments that have been drawn up, a directed issue of shares to the guarantors in the Rights Issue who have chosen to receive guarantee compensation in the form of newly issued shares in the Company (the "Compensation Issue") is implemented. The subscription price in the Compensation Issue is set at SEK 1.80 per share and payment is made through set-off of the guarantors' claims.


Omvandling av betalda tecknade units (BTU) till aktier och teckningsoptioner av serie 2021

Uppsala, 1 juli 2020. Dicot AB (publ) ("Dicot" eller "Bolaget") har genomfört en företrädesemission om cirka 21,8 MSEK ("Företrädesemissionen"). Företrädesemissionen tecknades till 326 procent. Totalt emitterades 5 453 576 units i Företrädesmissionen motsvarande 21 814 304 aktier och 21 814 304 teckningsoptioner av serie 2021 (TO2).


Conversion of paid subscribed units (BTU) to shares and warrants of series 2021

Dicot AB (publ) ("Dicot" or the "Company") has conducted a rights issue of approximately SEK 21.8 million (the "Rights Issue"). The Rights Issue was subscribed with 326 percent. In total, 5,453,576 units were issued in the Rights Issue consisting of 21,814,304 shares and 21,814,304 warrants of series 2021 (TO2).


Dicots företrädesemission kraftigt övertecknad

Pressmeddelande: Uppsala, 24 juni 2020. Företrädesemissionen om 21,8 MSEK som offentliggjordes den 23 april 2020 och som godkändes av årsstämman den 26 maj 2020 ("Företrädesemissionen") i Dicot AB (publ) ("Dicot" eller "Bolaget") blev kraftigt övertecknad. Företrädesemissionen tecknades till totalt 326 procent. Genom Företrädesemissionen tillförs Bolaget cirka 21,8 MSEK före emissionskostnader.


Dicot's rights issue is heavily oversubscribed

Press release: Uppsala, June 24, 2020. The rights issue of SEK 21.8 million which was disclosed on April 23, 2020 and resolved by the annual general meeting on May 26, 2020 (the "Rights Issue")  in Dicot AB (publ) ("Dicot" or the "Company") has been heavily oversubscribed. The Rights Issue was subscribed to 326 percent. Through the Rights Issue, the Company obtains approximately SEK 21.8 million before issue costs.


Dicot hemsida nu tvåspråkig

Uppsala, 16 juni 2020. Dicot AB meddelar idag att bolaget lanserat en engelsk version av hemsidan www.dicot.se , ett steg framåt för att nå ut till internationella aktörer.


Dicot's website in English

Uppsala, June 16, 2020. Dicot AB announces that the company has launched an English version of the website www.dicot.se, a step forward to reach the international market.


Dicots uppmuntrar till dialog kring sexuell hälsa

Dicot AB har förstärkt hemsidan med möjligheten att ställa frågor kring sexuell hälsa och sexuell dysfunktion. Se Dicots hemsida: www.dicot.se/patient-sexuell-haelsa


Ny styrelseledamot förstärker Dicots styrelse

Pressmeddelande: Uppsala, 10 juni 2020. Årsstämman i Dicot AB (publ) beslutade att välja in Claes Post som ny styrelseledamot i Dicots styrelse.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90

Om beQuoted